MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

Nicholas G NickolsRamin NazarianShuang G ZhaoVictor TanVladislav UzunangelovZheng XiaRobert BaertschElad NeemanAllen C GaoGeorge V ThomasLauren HowardAmanda M De HoedtJosh StuartTheodore GoldsteinKim ChiMartin E GleaveJulie N GraffTomasz M BeerJustin M DrakeChristopher P EvansRahul AggarwalAdam FoyeFelix Y FengEric J SmallWilliam J AronsonStephen J FreedlandOwen N WitteJiaoti HuangJoshi J AlumkalRobert E ReiterMatthew B Rettig

Published in: Prostate cancer and prostatic diseases (2019)

We conclude that pharmacologic targeting of the MEK/ERK pathway may be a viable treatment strategy for patients with refractory metastatic prostate cancer. An ongoing Phase II trial tests this hypothesis.

Keyphrases

pi k akt
prostate cancer
signaling pathway
squamous cell carcinoma
small cell lung cancer
cell proliferation
radical prostatectomy
cancer therapy
placebo controlled
study protocol